Subscribe free

Cytoreductive Surgery & Peritoneum ·

Screening improves survival outcomes in colorectal peritoneal metastases.

Analysis of 2,773 colorectal peritoneal metastasis patients revealed that those diagnosed through screening had significantly better survival rates and more often received curative treatment. Specifically, 7% were screen-detected, with a median overall survival of 20 months compared to 10.8 months for clinically detected patients. Additionally, 28% of screen-detected patients underwent cytoreductive surgery with hyperthermic intraperitoneal chemotherapy, versus only 14% in the clinically detected cohort, underscoring the advantages of early detection.

Journal Article by Galanos LJK, Rijken A (…) de Hingh IHJT et 10 al. in Eur J Surg Oncol

Copyright © 2024 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

read the whole article in Eur J Surg Oncol

open it in PubMed

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in Cytoreductive Surgery & Peritoneum.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

Specialty newsletters: every new paper in your field, as a list of titles linked to the source. Daily Selection: the five that matter, cut to their key points.

FreeNo spamOne-click unsubscribe

More in Cytoreductive Surgery & Peritoneum

The latest stitches

Ann Surg Oncol28 Aug 2026

Prophylactic HIPEC Improves Survival in Advanced Colorectal Cancer

Prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) significantly enhances peritoneal metastasis-free survival and disease-free survival in patients with locally advanced colorectal cancer, though overall survival rates and complication rates remain unchanged.

All papers in Cytoreductive Surgery & Peritoneum →